scPharmaceuticals Provides FUROSCIX® (furosemide injection) Commercial Update
January 30, 2023 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Jan. 30, 2023 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Announces Appointment of Rachael Nokes as Chief Financial Officer
December 19, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Dec. 19, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Participate in the 12th Annual LifeSci Partners Corporate Access Event
December 14, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Dec. 14, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces Pricing of $50 Million Public Offering
November 22, 2022 08:01 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Announces Proposed Underwritten Public Offering of Common Stock
November 21, 2022 16:01 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Nov. 21, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
November 09, 2022 16:05 ET
|
scPharmaceuticals, Inc.
Announced FDA marketing approval of FUROSCIX® (furosemide injection), the first and only self-administered, subcutaneous loop diuretic for the at-home treatment of congestion in chronic heart failure ...
scPharmaceuticals to Participate in the Jefferies London Healthcare Conference
November 02, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals to Announce Third Quarter 2022 Financial Results and Host Conference Call on November 9, 2022
October 26, 2022 08:00 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Oct. 26, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
UPDATE - scPharmaceuticals Announces FDA Approval of FUROSCIX® (furosemide injection), the First and Only Self-administered, Subcutaneous Loop Diuretic for the At-home Treatment of Congestion in Chronic Heart Failure
October 10, 2022 09:41 ET
|
scPharmaceuticals, Inc.
FUROSCIX demonstrated 99.6% bioavailability and produced similar diuresis and natriuresis compared to intravenous furosemide Commercial launch planned in Q1 2023 BURLINGTON, Mass., Oct. 10, 2022 ...
scPharmaceuticals Announces $100 Million Debt Financing Agreement with Oaktree
October 10, 2022 08:05 ET
|
scPharmaceuticals, Inc.
BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...